Skip to main content
  • TAVR Patients Frequently Develop Subclinical Leaflet Thrombosis, Risking Ischemic Events

    Oral anticoagulation lowers SLT risk by 58% vs. antiplatelet regimens

    Subclinical leaflet thrombosis (SLT) is a “frequent phenomenon” of biological prostheses used in transcatheter aortic valve replacement (TAVR), which, left untreated, raises the risk of unfavorable clinical outcomes such as cerebral ischemic events, according to a new meta-analysis of more than 11,000 patients.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details